| ATNM |
Actinium Pharmaceuticals, Inc. |
72%
|
her strengthens our supply chain, reducing environmental impact while maximizing resource utilization. We recognize that the future of isotope supply lies in our ability to anticipate and respond to … |
| ATNM |
Actinium Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from ATNM graph: Reciprocal relationship from TLX graph: Reciprocal relationship from ATNM graph: Reciprocal relationship from TLX graph: her strengthens our supply chain, red… |
| BSX |
Boston Scientific Corporation |
72%
|
her strengthens our supply chain, reducing environmental impact while maximizing resource utilization. We recognize that the future of isotope supply lies in our ability to anticipate and respond to … |
| BSX |
Boston Scientific Corporation |
72%
|
Reciprocal relationship from BSX graph: Reciprocal relationship from TLX graph: her strengthens our supply chain, reducing environmental impact while maximizing resource utilization. We recognize tha… |
| BTAI |
BioXcel Therapeutics, Inc. |
72%
|
her strengthens our supply chain, reducing environmental impact while maximizing resource utilization. We recognize that the future of isotope supply lies in our ability to anticipate and respond to … |
| BTAI |
BioXcel Therapeutics, Inc. |
72%
|
Reciprocal relationship from BTAI graph: Reciprocal relationship from TLX graph: her strengthens our supply chain, reducing environmental impact while maximizing resource utilization. We recognize th… |
| CATX |
Perspective Therapeutics, Inc. |
72%
|
Reciprocal relationship from CATX graph: Reciprocal relationship from TLX graph: Reciprocal relationship from CATX graph: Reciprocal relationship from TLX graph: her strengthens our supply chain, red… |
| CATX |
Perspective Therapeutics, Inc. |
72%
|
her strengthens our supply chain, reducing environmental impact while maximizing resource utilization. We recognize that the future of isotope supply lies in our ability to anticipate and respond to … |
| CLRB |
Cellectar Biosciences, Inc. |
72%
|
her strengthens our supply chain, reducing environmental impact while maximizing resource utilization. We recognize that the future of isotope supply lies in our ability to anticipate and respond to … |
| CLRB |
Cellectar Biosciences, Inc. |
72%
|
Reciprocal relationship from CLRB graph: Reciprocal relationship from TLX graph: her strengthens our supply chain, reducing environmental impact while maximizing resource utilization. We recognize th… |
| JANX |
Janux Therapeutics, Inc. |
72%
|
Reciprocal relationship from JANX graph: Reciprocal relationship from TLX graph: Reciprocal relationship from JANX graph: Reciprocal relationship from TLX graph: her strengthens our supply chain, red… |
| JANX |
Janux Therapeutics, Inc. |
72%
|
her strengthens our supply chain, reducing environmental impact while maximizing resource utilization. We recognize that the future of isotope supply lies in our ability to anticipate and respond to … |
| LNTH |
Lantheus Holdings, Inc. |
72%
|
her strengthens our supply chain, reducing environmental impact while maximizing resource utilization. We recognize that the future of isotope supply lies in our ability to anticipate and respond to … |
| LNTH |
Lantheus Holdings, Inc. |
72%
|
Reciprocal relationship from LNTH graph: ial financial, manufacturing, sales and marketing, distribution and other resources. • For PYLARIFY, our principal competitors are currently Telix Pharmaceuti… |
| MNPR |
Monopar Therapeutics Inc. |
72%
|
Reciprocal relationship from MNPR graph: Reciprocal relationship from TLX graph: Reciprocal relationship from MNPR graph: Reciprocal relationship from TLX graph: Reciprocal relationship from MNPR gra… |
| RADX |
Radiopharm Theranostics Limited |
72%
|
Reciprocal relationship from RADX graph: Reciprocal relationship from TLX graph: her strengthens our supply chain, reducing environmental impact while maximizing resource utilization. We recognize th… |
| RADX |
Radiopharm Theranostics Limited |
72%
|
her strengthens our supply chain, reducing environmental impact while maximizing resource utilization. We recognize that the future of isotope supply lies in our ability to anticipate and respond to … |
| REGN |
Regeneron Pharmaceuticals, Inc. |
72%
|
her strengthens our supply chain, reducing environmental impact while maximizing resource utilization. We recognize that the future of isotope supply lies in our ability to anticipate and respond to … |
| REGN |
Regeneron Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from REGN graph: Reciprocal relationship from TLX graph: her strengthens our supply chain, reducing environmental impact while maximizing resource utilization. We recognize th… |
| SNSE |
Sensei Biotherapeutics, Inc. |
72%
|
Reciprocal relationship from SNSE graph: Reciprocal relationship from TLX graph: her strengthens our supply chain, reducing environmental impact while maximizing resource utilization. We recognize th… |
| SNSE |
Sensei Biotherapeutics, Inc. |
72%
|
her strengthens our supply chain, reducing environmental impact while maximizing resource utilization. We recognize that the future of isotope supply lies in our ability to anticipate and respond to … |
| STQN |
Strategic Acquisitions, Inc. |
72%
|
Reciprocal relationship from STQN graph: Reciprocal relationship from TLX graph: Reciprocal relationship from STQN graph: Reciprocal relationship from TLX graph: Reciprocal relationship from STQN gra… |
| STQN |
Strategic Acquisitions, Inc. |
72%
|
ty of the members of either our board of directors or 167 our global management team are U.S. citizens or residents; (ii) more than 50% of our assets are located in the U.S.; or (iii) our business is… |
| FEB-32-HSBC-AUSTRALIA-LTD |
FEB-32-HSBC-AUSTRALIA-LTD |
62%
|
ssued 8,912 Contingent consideration 7,662 Total consideration 19,859 Recognized amounts of identifiable assets acquired and liabilities assumed Cash and cash equivalents 394 Trade and other receivab… |
| FEB-32-HSBC-BANK-AUSTRALIA-LTD |
FEB-32-HSBC-BANK-AUSTRALIA-LTD |
62%
|
ated milestones will be expensed. F-43 The fair values of identifiable assets on acquisition are outlined below: Fair value Consideration US$'000 1. Cash paid 6,521 Acquisition related costs 31 Defer… |
| GRAND-PHARMACEUTICAL-GROUP-LIMITED |
GRAND-PHARMACEUTICAL-GROUP-LIMITED |
62%
|
apital management framework is to maintain, monitor and secure access to future funding arrangements to finance the necessary research and development activities being performed by the Group. 24. Con… |
| GROUP-THE-GROUP |
GROUP-THE-GROUP |
62%
|
ts are required. Accrued R&D expenditure The Group is required to estimate its accrued expenses at each reporting date, which involves reviewing open contracts and purchase orders, communicating with… |
| HSBC-BANK-AUSTRALIA-LIMITED |
HSBC-BANK-AUSTRALIA-LIMITED |
62%
|
ssued 8,912 Contingent consideration 7,662 Total consideration 19,859 Recognized amounts of identifiable assets acquired and liabilities assumed Cash and cash equivalents 394 Trade and other receivab… |
| IMBC-GROUP |
IMBC-GROUP |
62%
|
ssued 8,912 Contingent consideration 7,662 Total consideration 19,859 Recognized amounts of identifiable assets acquired and liabilities assumed Cash and cash equivalents 394 Trade and other receivab… |
| ISOTHERAPEUTICS-GROUP-LLC |
ISOTHERAPEUTICS-GROUP-LLC |
62%
|
operties Motor vehicles Total A$’000 A$’000 A$’000 Balance at January 1, 2024 6,134 1,189 7,323 Additions - 2,166 2,166 Acquisition of businesses 1,687 - 1,687 Depreciation charge ( 1,704 ) ( 628 ) (… |
